About 259,830 results

Gocovri Clinical Data

May 27th, 2020 - The efficacy and safety of GOCOVRI® 274 mg were evaluated in two Phase 3, randomized, placebo-controlled trials

Early indicators: Investigational convalescent plasma is safe for patients with COVID-19

Mayo Clinic and collaborators today reported safety data on the first 5,000 hospitalized patients transfused with investigational convalescent plasma as part of the Food and Drug Administration’s national Expanded Access Program (EAP) for COVID-19. The early indicators suggest experimental convalescent plasma is safe in treating severely ill patients. At this time, convalescent plasma is the on...

KALYDECO® (ivacaftor) - For Healthcare Professionals

Helpful information for your patients. Get product information intended for healthcare professionals. Resources. About KALYDECO. Studies and Data.

ENSPRYNG™ (satralizumab-mwge) - New FDA Approved...

Explore ENSPRYNG™ As A New Treatment Option For Your Patients. Contraindications. Prescribing Information. Safety Info. Dosing & Admin. Types: Financial Assistance, ENSPRYNG Access Solutions, Clinical Trial Data, Patient Resources.

QINLOCK (ripretinib) - Health Care Professional Site‎

Learn more about the mechanism of action of QINLOCK. Request more information today. Download the QINLOCK clinical efficacy and safety overview for healthcare professionals. Resources. Support Your Patients. View Dosing Information. FDA Approved. Clinical Data.

JELMYTO - Official HCP Website - See Prescribing Information‎

Read More Information About JELMYTO™ (mitomycin) for pyelocalyceal solution. Dosing Information. Healthcare Professionals. Key Clinical Data.

Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
Eli Lilly and Company

Mar 9th, 2021 - INDIANAPOLIS, March 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together significantly reduced COVID-19 related hospitalizations and deaths ("events") in high-risk patients recently diagnosed with CO...

TABRECTA™ (capmatinib) - Now Approved - HCP Site‎

HCPs, Visit The Official Site For Information About TABRECTA™ As A Treatment Option. See If TABRECTA™ Could Be Right For Your Patients. Full Safety Profile. Patient Co-Pay Program. Mechanism Of Action. Newly FDA Approved. Official HCP Website. Clinical Trial Data.

ADZENYS XR-ODT® (amphetamine tablets)

Find information on Adzenys XR-ODT delivery system, dosing, adverse reactions, and safety data. Learn about savings and support available to your patients. View Important Safety Information including Boxed WARNING for abuse and dependence.

KAZANO (alogliptin and metformin HCI)

Read about KAZANO efficacy including recommended dosing, clinical data, and safety profile. See Important Safety Information and Prescribing Information.

MENVEO (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine)

In clinical trials, MENVEO demonstrated noninferior head-to-head immunogenicity data compared to Menactra and has the broadest age indication for MenACWY vaccination

PREVELEAK® Surgical sealant - BioSurgery

HCPs: Find efficacy and safety data plus additional product information about PREVELEAK, a surgical sealant for use in vascular reconstructions.

OPDIVO (nivolumab) injection

Learn more about OPDIVO® (nivolumab). Prescribed medication to treat certain types of cancers. Read about its indications, clinical data and efficacy.

BROMSITE™ (bromfenac ophthalmic solution, 0.075%)

Learn about dosage and administration, clinical trial and safety data, and information for patients and caregivers, including a savings offer.


UV Elements Broad-Spectrum SPF 44 ... The Skin Cancer Foundation recommends this product as an effective broad spectrum sunscreen. EltaMD UV Elements


Find HCP resources for ERBITUX (cetuximab) and download efficacy data and safety information from clinical trials.


Based on IMS data November 2013 to June 2017. Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

KYPROLIS (carfilzomib) for injection

Learn about clinical trial data for KYPROLIS® (carfilzomib)—treats relapsed or refractory multiple myeloma.

RAPLIXA (Fibrin sealant (human)

HCPs: Find efficacy and safety data plus additional product information about RAPLIXA, the first and only powder fibrin sealant.

RETAVASE® (reteplase)

See the full Prescribing Information for RETAVASE® (reteplase)–available from Chiesi. Find links for clinical trial data, dosing, ordering, and more.